Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna Inc. shares rose 19% in their trading debut after the biotechnology company raised $288 million in an enlarged ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...

Recent health news highlights include high costs of weight-loss drugs like Wegovy, Septerna's strong Nasdaq debut, ...

Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Global stocks were trading higher on Friday, although they were set for a weekly loss amid US election jitters, while oil ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...